Jefferies initiates Arrowhead Research at Buy on RNAi platform potential

Recent private offering placement agent Jefferies initiates coverage on Arrowhead Research (ARWR +4.3%) with a Buy and PT of $15.

Analyst Thomas Wei believes Arrowhead's differentiated RNAi platform is its "key value driver." And, as ARC-520 for hepatitis B progresses, "it should provide confidence around safety and mechanistic validation for the technology, even if HBV cures are not achieved. We expect expansion into liver targeted orphan diseases should create significant value."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs